ATRA Stock Overview
Engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
My Notes
Capture your thoughts, links and company narrative
Atara Biotherapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.51 |
| 52 Week High | US$25.00 |
| 52 Week Low | US$5.40 |
| Beta | 0.46 |
| 1 Month Change | -37.63% |
| 3 Month Change | -7.07% |
| 1 Year Change | -49.10% |
| 3 Year Change | -97.20% |
| 5 Year Change | -96.92% |
| Change since IPO | -96.50% |
Recent News & Updates
Atara Biotherapeutics: Another Dip Buying Opportunity Following CRL For CMC Issues
Jan 21Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Boosted 25% But Its Business Prospects Need A Lift Too
Jan 16
Recent updates
Atara Biotherapeutics: Another Dip Buying Opportunity Following CRL For CMC Issues
Jan 21Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Boosted 25% But Its Business Prospects Need A Lift Too
Jan 16Is Atara Biotherapeutics (NASDAQ:ATRA) In A Good Position To Deliver On Growth Plans?
Jan 07Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement
Nov 06Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement
Sep 06Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock Catapults 34% Though Its Price And Business Still Lag The Industry
Jul 21Atara Biotherapeutics: An Underestimated Contender In Autoimmune Diseases CAR-T Cell Therapy
Jul 03New Forecasts: Here's What Analysts Think The Future Holds For Atara Biotherapeutics, Inc. (NASDAQ:ATRA)
May 14Revenues Working Against Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Following 26% Dive
May 11Atara Biotherapeutics: Opportunity As They Sell Off Their Approved Asset For Longer Runway
Feb 06Here's Why Atara Biotherapeutics (NASDAQ:ATRA) Must Use Its Cash Wisely
Oct 17Earnings Working Against Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Following 32% Dive
May 18Need To Know: Analysts Are Much More Bullish On Atara Biotherapeutics, Inc. (NASDAQ:ATRA)
Feb 13Shareholder Returns
| ATRA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 23.8% | 3.5% | 0.6% |
| 1Y | -49.1% | 2.9% | 22.4% |
Return vs Industry: ATRA underperformed the US Biotechs industry which returned 2.9% over the past year.
Return vs Market: ATRA underperformed the US Market which returned 22.4% over the past year.
Price Volatility
| ATRA volatility | |
|---|---|
| ATRA Average Weekly Movement | 22.1% |
| Biotechs Industry Average Movement | 11.4% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ATRA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ATRA's weekly volatility has increased from 17% to 22% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 159 | Cokey Nguyen | www.atarabio.com |
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis.
Atara Biotherapeutics, Inc. Fundamentals Summary
| ATRA fundamental statistics | |
|---|---|
| Market cap | US$53.80m |
| Earnings (TTM) | -US$133.16m |
| Revenue (TTM) | US$100.44m |
0.6x
P/S Ratio-0.5x
P/E RatioIs ATRA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATRA income statement (TTM) | |
|---|---|
| Revenue | US$100.44m |
| Cost of Revenue | US$180.37m |
| Gross Profit | -US$79.93m |
| Other Expenses | US$53.23m |
| Earnings | -US$133.16m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -23.12 |
| Gross Margin | -79.58% |
| Net Profit Margin | -132.58% |
| Debt/Equity Ratio | 0% |
How did ATRA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/06 23:33 |
| End of Day Share Price | 2025/02/06 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Atara Biotherapeutics, Inc. is covered by 15 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Newman | Canaccord Genuity |
| Yigal Nochomovitz | Citigroup Inc |
| Jonathan Miller | Evercore ISI |